SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The index is trending amid volatility as traders weigh rising bond yields and geopolitical tensions against ongoing support from tech sector performance. Discussion remains fragmented, with bears focusing on a potential September correction while bulls anticipate continued momentum.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending amid ongoing debate over its long-term valuation, with investors weighing the company's significant contracted backlog and infrastructure buildout against macro-economic headwinds and market volatility. While some traders express frustration with the recent price consolidation, long-term investors emphasize strong fundamentals and the company's position as an AI data center builder.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

The discussion around SOXL is dominated by intense community frustration regarding the ETF's performance relative to its underlying semiconductor components, with many traders labeling it a 'scam' or 'rigged' due to perceived tracking errors and volatility. Investors are primarily focused on positioning ahead of upcoming Nvidia earnings and debating whether the current price action signals a deeper semiconductor correction or a potential bounce.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trading in a tight, range-bound pattern as traders weigh concerns over rising U.S. Treasury yields and geopolitical tensions against the resilience of mega-cap tech stocks. Market participants remain divided, with some betting on a seasonal September correction while others focus on continued institutional support for the AI sector.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is experiencing significant volatility and debate, with a recent collaboration update involving Panasonic and JANCTION sparking conflicting reactions. While some traders view the news as a positive catalyst for future utility and adoption, others remain skeptical, dismissing the project as a scam and pointing to poor price performance and lack of clear revenue impact.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors react to the company's autonomous vehicle progress, specifically the expansion of its Robotaxi fleet in Austin ahead of an upcoming product launch event. While bulls point to this momentum and robot-related developments as a positive catalyst, bears remain skeptical, framing the price action as a potential "sell the news" setup or an unsustainable speculative pump.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

SOXS is trending as traders debate the sustainability of the semiconductor sector's AI-driven rally, with many expressing bearish sentiment based on concerns over valuation, sector debt, and broader economic headwinds. Community sentiment remains polarized, with some traders actively shorting or buying the dip while others caution against the structural decay inherent in leveraged inverse ETFs.

Investment Managers Series Trust II - Tradr 2X Short NBIS Daily ETF

Tradr 2X Short NBIS Daily ETF

NBIZ is experiencing significant volatility as traders use the 2x leveraged inverse ETF to bet against NBIS, with the conversation dominated by intense debate over AI sector valuation, short-squeeze potential, and the risks of holding leveraged vehicles that suffer from volatility decay. While some traders report locking in profits from short-term price swings, others express frustration over the complex tracking of the fund during rapid market moves.

JinkoSolar Holding Co., Ltd. engages in the manufacture of solar modules. It distributes solar products and sells its solutions and services to a diversified international utility, commercial and residential customers. The company was founded by Xian De Li, Kang Ping Chen, and Xian Hua Li in June 2006 and is headquartered in Shangrao, China.

JinkoSolar Holding Co. Ltd - ADR

JinkoSolar Holding Co LTD

JinkoSolar is trending due to investor focus on its deeply discounted valuation, with many traders pointing to its large revenue base relative to its small market capitalization and the potential for a share buyback. While some investors express bullish sentiment regarding the company's technology leadership and energy storage potential, others remain cautious due to broader industry headwinds, including margin compression and market oversupply.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to positive Phase 3 clinical trial results for its LSD-based treatment in generalized anxiety disorder, which analysts indicate de-risks the company's lead asset and supports a multibillion-dollar commercial opportunity. While some traders debate the long-term scalability of in-clinic psychedelic therapy and the impact of a recent large equity offering, community sentiment remains largely bullish ahead of further trial results and anticipated regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Centene (CNC) Outpaced Other Medical Stocks This Year?

Here is how Centene (CNC) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data

Equity

The biotech firm reported strong Phase 2 trial results for a blood cancer treatment, along with a $140 million fundraise to support the next stages of the trial.

Insider Signals and Potential Moonshots that Could Reset Valuations

Biotech and pharma markets are leading the way in a sharply selective environment at midday, where clinical data, insider conviction, and platform scalability are driving outsized moves while weaker narratives get left behind. $NTHI, $POET, $SDOT, $BDRX, $CLRB, $DOCN, $FSLY, $EWTX, $BLDP

Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses

Cellectar releases Phase 2b CLOVER WaM data showing strong response rates and durability, alongside $140 million financing.read more...

Markets On Fire: Biotech Breakthroughs and AI Mega-Deals Move Wall Street

$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks

Insights into Cellectar Biosciences's Upcoming Earnings

Earnings Outlook For Cellectar Biosciences

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 


All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy

Reported GAAP EPS of -$0.57 up 83.19% YoY

Cellectar Biosciences faces ongoing financial pressure characterized by a widening net loss and rising research and development costs, alongside structural risks inherent in the clinical-stage drug discovery and development process.

Cellectar Biosciences is advancing its oncology pipeline with positive clinical data for iopofosine I 131 and has secured sufficient capital to support its operational roadmap through the second quarter of 2027.

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Cellectar Biosciences Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLRB Cellectar Biosciences Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest CLRB News